verapamil has been researched along with Local Neoplasm Recurrence in 15 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous in vitro and in vivo results suggested that hydroxyurea (HU) and verapamil could suppress meningioma growth individually and synergistically." | 9.22 | Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies. ( Barth, T; Burt, L; Dunson, W; Gillespie, DL; Hoang, N; Jensen, RL; Karsy, M, 2016) |
| "We investigated whether verapamil (VR), a known chemosensitizing agent of P-glycoprotein-mediated multidrug resistance, could enhance the preventative effect of doxorubicin (Adriamycin, ADM) on both intravesical recurrence and disease progression after transurethral resection (TUR) of superficial bladder cancer." | 9.08 | Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological On ( Ariyoshi, A; Hiratsuka, Y; Iguchi, A; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K, 1998) |
| "A collaborative randomized clinical trial on the intravesical administration of Adriamycin (ADM) with or without verapamil (VR), a calcium-channel blocker, as chemotherapy of superficial bladder cancer (Ta, T1) was carried out at two universities, Okayama and Kagoshima, and their affiliated hospitals." | 9.07 | Intravesical instillation chemotherapy of adriamycin with or without verapamil for the treatment of superficial bladder cancer: the final results of a collaborative randomized trial. ( Kawahara, M; Matsumura, Y; Ohashi, Y; Ohi, Y; Ohmori, H; Shirahama, T; Tsushima, T, 1994) |
| "A prospective randomized trial was conducted to compare the prophylactic effect of intravesical installation of Adriamycin (ADM) plus verapamil (VR) with that of ADM alone for recurrence of superficial bladder cancer." | 9.07 | Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results. The Kyushu University Urological Oncology Group. ( Ariyoshi, A; Hiratsuka, Y; Iguchi, A; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1994) |
| "A case-controlled collaborative study on the intravesical administration of Adriamycin in the presence or absence of verapamil, a calcium-channel blocker, as chemotherapy of superficial bladder cancer was carried out at two universities, Okayama and Kagoshima, and their affiliated hospitals." | 9.07 | Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study. ( Kawahara, M; Matsumura, Y; Ohashi, Y; Ohi, Y; Ohmori, H; Shirahama, T; Tsushima, T, 1992) |
| "Nineteen patients with histologically proven superficial bladder cancer (Ta, T1) were treated with intravesical instillation of 30 mg of adriamycin (ADM) dissolved in 24 ml physiological saline plus 15 mg of verapamil (VR) (6 ml) every day for 10 days." | 7.68 | Intravesical therapy with adriamycin plus verapamil in patients with superficial bladder cancer: a pilot study. ( Ariyoshi, A; Iguchi, A; Kimiya, K; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1992) |
| "The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs." | 5.28 | Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. ( Dalton, WS; Durie, BG; Grogan, TM; Meltzer, PS; Miller, TP; Salmon, SE; Scheper, RJ; Taylor, CW, 1989) |
| "Previous in vitro and in vivo results suggested that hydroxyurea (HU) and verapamil could suppress meningioma growth individually and synergistically." | 5.22 | Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies. ( Barth, T; Burt, L; Dunson, W; Gillespie, DL; Hoang, N; Jensen, RL; Karsy, M, 2016) |
| "We investigated whether verapamil (VR), a known chemosensitizing agent of P-glycoprotein-mediated multidrug resistance, could enhance the preventative effect of doxorubicin (Adriamycin, ADM) on both intravesical recurrence and disease progression after transurethral resection (TUR) of superficial bladder cancer." | 5.08 | Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological On ( Ariyoshi, A; Hiratsuka, Y; Iguchi, A; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K, 1998) |
| "A collaborative randomized clinical trial on the intravesical administration of Adriamycin (ADM) with or without verapamil (VR), a calcium-channel blocker, as chemotherapy of superficial bladder cancer (Ta, T1) was carried out at two universities, Okayama and Kagoshima, and their affiliated hospitals." | 5.07 | Intravesical instillation chemotherapy of adriamycin with or without verapamil for the treatment of superficial bladder cancer: the final results of a collaborative randomized trial. ( Kawahara, M; Matsumura, Y; Ohashi, Y; Ohi, Y; Ohmori, H; Shirahama, T; Tsushima, T, 1994) |
| "A prospective randomized trial was conducted to compare the prophylactic effect of intravesical installation of Adriamycin (ADM) plus verapamil (VR) with that of ADM alone for recurrence of superficial bladder cancer." | 5.07 | Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results. The Kyushu University Urological Oncology Group. ( Ariyoshi, A; Hiratsuka, Y; Iguchi, A; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1994) |
| "A case-controlled collaborative study on the intravesical administration of Adriamycin in the presence or absence of verapamil, a calcium-channel blocker, as chemotherapy of superficial bladder cancer was carried out at two universities, Okayama and Kagoshima, and their affiliated hospitals." | 5.07 | Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study. ( Kawahara, M; Matsumura, Y; Ohashi, Y; Ohi, Y; Ohmori, H; Shirahama, T; Tsushima, T, 1992) |
| "Nineteen patients with histologically proven superficial bladder cancer (Ta, T1) were treated with intravesical instillation of 30 mg of adriamycin (ADM) dissolved in 24 ml physiological saline plus 15 mg of verapamil (VR) (6 ml) every day for 10 days." | 3.68 | Intravesical therapy with adriamycin plus verapamil in patients with superficial bladder cancer: a pilot study. ( Ariyoshi, A; Iguchi, A; Kimiya, K; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1992) |
| "Our data suggest that ovarian cancer contain small sub-population of side population cells which shares some characteristics of stem cells." | 1.42 | Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer. ( Dou, HT; Liu, PS; Xu, P; Zhang, QH; Zhuang, SC, 2015) |
| "P-glycoprotein can be expressed on bladder cancer cells without prior chemotherapy." | 1.29 | P-glycoprotein expression in bladder cancer. ( Flint, A; Grossman, HB; Liebert, M; Noto, L; Park, J; Shinohara, N, 1994) |
| "The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs." | 1.28 | Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. ( Dalton, WS; Durie, BG; Grogan, TM; Meltzer, PS; Miller, TP; Salmon, SE; Scheper, RJ; Taylor, CW, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 9 (60.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ham, SW | 1 |
| Jeon, HY | 1 |
| Kim, H | 1 |
| Zhang, QH | 1 |
| Dou, HT | 1 |
| Xu, P | 1 |
| Zhuang, SC | 1 |
| Liu, PS | 1 |
| Karsy, M | 1 |
| Hoang, N | 1 |
| Barth, T | 1 |
| Burt, L | 1 |
| Dunson, W | 1 |
| Gillespie, DL | 1 |
| Jensen, RL | 1 |
| Takeshita, A | 1 |
| Park, J | 1 |
| Shinohara, N | 1 |
| Liebert, M | 1 |
| Noto, L | 1 |
| Flint, A | 1 |
| Grossman, HB | 1 |
| Liu, NB | 1 |
| Tsushima, T | 2 |
| Ohmori, H | 3 |
| Ohi, Y | 2 |
| Shirahama, T | 2 |
| Kawahara, M | 2 |
| Matsumura, Y | 3 |
| Ohashi, Y | 2 |
| Naito, S | 3 |
| Ueda, T | 2 |
| Kotoh, S | 2 |
| Iguchi, A | 3 |
| Sagiyama, K | 3 |
| Hiratsuka, Y | 2 |
| Osada, Y | 3 |
| Ariyoshi, A | 3 |
| Omoto, T | 3 |
| Kumazawa, J | 3 |
| Powles, R | 1 |
| Raje, N | 1 |
| Milan, S | 1 |
| Millar, B | 1 |
| Shepherd, V | 1 |
| Mehta, J | 1 |
| Singhal, S | 1 |
| Kulkarni, S | 1 |
| Viner, C | 1 |
| Gore, M | 1 |
| Cunningham, D | 1 |
| Treleaven, J | 1 |
| Kimiya, K | 1 |
| Lukkarinen, O | 1 |
| Paul, C | 1 |
| Hellström, P | 1 |
| Kontturi, M | 1 |
| Nurmi, M | 1 |
| Puntala, P | 1 |
| Ottelin, J | 1 |
| Tammela, T | 1 |
| Tidefeldt, U | 1 |
| Dalton, WS | 1 |
| Grogan, TM | 1 |
| Meltzer, PS | 1 |
| Scheper, RJ | 1 |
| Durie, BG | 1 |
| Taylor, CW | 1 |
| Miller, TP | 1 |
| Salmon, SE | 1 |
| Yoshimoto, J | 1 |
| Saegusa, M | 1 |
| Ochi, J | 1 |
| Hara, M | 1 |
| Akagi, T | 1 |
| Obama, T | 1 |
| Tanahashi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combination of Hydroxyurea and Verapamil for Refractory Meningiomas[NCT00706810] | Phase 2 | 8 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response and progression will be evaluated in this study using measurements from the MRI/CT scans. Measurements will be made of the image slice with the largest cross sectional area. Two orthogonal measures will be made to determine maximal AP and lateral dimensions. Progression of disease will be defined as a greater than 25% increase of largest cross sectional area by two orthogonal measurements, taking as reference the smallest sum recorded since the treatment started or the appearance of one or more new lesions. (NCT00706810)
Timeframe: 31 months
| Intervention | months (Median) |
|---|---|
| All Participants | 8.0 |
Adverse Events assessed in accordance with CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0. (NCT00706810)
Timeframe: two years
| Intervention | participants (Number) |
|---|---|
| All Groups | 0 |
1 review available for verapamil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2003 |
7 trials available for verapamil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biologi | 2016 |
Intravesical instillation chemotherapy of adriamycin with or without verapamil for the treatment of superficial bladder cancer: the final results of a collaborative randomized trial.
Topics: Administration, Intravesical; Adult; Aged; Cystoscopy; Doxorubicin; Drug Synergism; Drug Therapy, Co | 1994 |
Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results. The Kyushu University Urological Oncology Group.
Topics: Administration, Intravesical; Aged; Chemotherapy, Adjuvant; Doxorubicin; Drug Therapy, Combination; | 1994 |
Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood C | 1997 |
Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological On
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 1998 |
Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystoscopy; Doxo | 1992 |
Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumours.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Synerg | 1991 |
7 other studies available for verapamil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Verapamil augments carmustine- and irradiation-induced senescence in glioma cells by reducing intracellular reactive oxygen species and calcium ion levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Calcium Channels, L-Type; Carmustine; Cell | 2017 |
Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer.
Topics: Antigens, CD; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bindi | 2015 |
P-glycoprotein expression in bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Bindi | 1994 |
[Intravesical instillation of combined adriamycin and verapamil in preventing recurrence of superficial bladder tumor].
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Bindi | 1993 |
Intravesical therapy with adriamycin plus verapamil in patients with superficial bladder cancer: a pilot study.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Doxorubicin; Drug Therapy, Combina | 1992 |
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter | 1989 |
[Intravesical chemotherapy of adriamycin and verapamil in patients with recurrent superficial bladder cancer: preliminary report].
Topics: Administration, Intravesical; Adult; Aged; Doxorubicin; Drug Therapy, Combination; Humans; Male; Mid | 1987 |